Gary Abrams, MD
Bio paragraph coming soon
David S. Boyer, MD
David S. Boyer, M.D. is a Board-certified ophthalmologist specializing in the treatment of diseases of the retina and vitreous. Dr. Boyer is Senior Partner at Retina-Vitreous Associates Medical Group with offices in Los Angeles, Beverly Hills, North Hollywood, Torrance, Santa Clarita, Pasadena and Tarzana, California.
Dr. Boyer is a Clinical Professor of Ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, CA.
He has an extensive research background and is currently an investigator for various clinical trials. He is one of the leading retinal clinical researchers in the country for new treatments in macular degeneration and diabetic macular edema. A widely-published author and avid lecturer, Dr. Boyer lectures nationally and internationally on retinal research and the innovative approach to the treatment of retinal diseases.
Jeffrey S. Heier, MD
Jeffrey S. Heier, M.D., is the Co-President and Medical Director at Ophthalmic Consultants of Boston (OCB). He is also the Director of the Vitreoretinal Service and Director of Retina Research at OCB. Dr. Heier is one of the leading retinal clinical researchers in the country for new treatments in exudative and non-exudative macular degeneration, diabetic macular edema, venous occlusive disease, vitreoretinal surgical techniques and instrumentation, and diagnostic imaging of the retina.
Dr. Heier is on the Executive Board of the Retina Society, the Board of the American Society of Retina Specialists, and is President-Elect of the New England Ophthalmological Society. He is a scientific advisor to over thirty biotechnical or pharmaceutical companies, lectures nationally and internationally on research and innovative approaches to the treatment of retinal diseases, and has authored numerous works in peer-reviewed journals.
Dr. Heier received his medical degree from Boston University, then did a transitional internship and ophthalmology residency at Fitzsimons Army Medical Center. Between his internship and residency, he served as a physician in a Combat Support Hospital in the Persian Gulf War, where he was awarded a Bronze Star. Dr. Heier then completed a vitreoretinal fellowship at OCB/Tufts School of Medicine.
J. Timothy Stout, MD, PhD, MBA
Dr. Stout received his undergraduate degree from Rice University in Houston, and his medical degree and doctorate in molecular genetics from Baylor College of Medicine, where he also completed a post-doctoral fellowship in Human Genetics. He completed his Ophthalmology residency at the Doheny Eye Institute, University of Southern California, Los Angeles, a medical retina fellowship at Moorfields Eye Hospital in London and a surgical retinal fellowship at the Doheny Eye Institute. Dr. Stout earned his MBA at the University of Oregon.
Dr. Stout has been the Sid W. Richardson Professor and Margarett Root Brown Chair of the Department of Ophthalmology, and Director of the Cullen Eye Institute at Baylor College of Medicine since 2013. Prior to that he served as Professor in the Departments of Ophthalmology and Molecular Genetics, as well as Vice President for Commercialization Strategies at Oregon Health & Science University in Portland, Oregon. He has directed the Clayton Gene Therapy Laboratories since 1995.
Dr. Stout brings experience from both the research and clinical sides of medicine. His research interests include human gene and cell-based therapy for proliferative and inherited ocular disease, retinal disease genotype-phenotype correlation and ocular disease gene mapping and discovery.
George A. Williams, MD
George A. Williams, MD is Chair, Department of Ophthalmology, Director of the Beaumont Eye Institute and Vice Chief of Surgical Services for Academic Affairs at William Beaumont Hospital in Royal Oak, Michigan. He is Professor and Chair of Ophthalmology, Oakland University William Beaumont School of Medicine and a partner with Associated Retinal Consultants. He is on the faculty of the European School for Advanced Studies in Ophthalmology in Lugano, Switzerland. A graduate of Northwestern University Feinberg School of Medicine, he completed his residency in ophthalmology and his fellowship in vitreoretinal surgery at the Eye Institute of the Medical College of Wisconsin.
Dr. Williams has published over 200 articles and book chapters in the field of vitreoretinal surgery. He has participated as principal investigator or co-investigator in over 20 clinical trials. He is on the Board of Trustees of The American Academy of Ophthalmology. He is a recipient of the Special Recognition Award, the Secretariat Award and the Senior Achievement Award of the American Academy of Ophthalmology. He is past chair of the Retina Ophthalmic Technology Assessment Committee and a member of the Health Policy Committee of the American Academy of Ophthalmology. He represents the American Academy of Ophthalmology as a member of the Relative Value Update Committee of the American Medical Association. He is past president of the American Society of Retinal Specialists and the Michigan Society of Eye Physicians and Surgeons.
He serves on the editorial board of the journals, Retina, Retinal Physician, Retinal Cases and Brief Reports and Current Opinion in Ophthalmology. Dr. Williams is an associate examiner for the American Board of Ophthalmology and a member of The Retina Society, The Macula Society, the American Society of Retina Specialists, the Association of University Professors in Ophthalmology and the Club Jules Gonin.
Zhuo-Hua Pan, PhD
Dr. Zhuo-Hua Pan received his B.S. degree from the University of Science and Technology of China, his M.S. degree from the Institute of Biophysics of Chinese Academic of Science, and his Ph.D. in biophysics from the State University of New York at Buffalo. He worked as an instructor and then an assistant professor at Harvard Medical School from 1991-1999. He joined the Department of Anatomy and Cell Biology at Wayne State University School of Medicine in 1999. He is currently Scientific Director of the Ligon Research Center of Vision and the Edward T. and Ellen K. Dryer Endowed Professor in Vision and Blindness Research for the WSU Department of Ophthalmology and Kresge Eye Institute.
Dr. Pan’s research focuses on the basic mechanisms of visual information processing by the retina and the development of optogenetic approaches to restoring vision to the blind. His research has been funded by NIH since 1996. His work has been published in many high-prestige journals, including in Nature, Neuron, PNAS, and Journal of Neuroscience, among others. His recent groundbreaking work on using channelrhodopsins to restore retinal light sensitivity to blind mice has been widely reported by the scientific community and news media, such as NIH press release, Research Highlights in Nature, Daily News in Science, New Scientist, and New York Times. He is the recipient of many awards, including Faculty Research Excellence Award at WSU School of Medicine, WSU Board of Governors Faculty Recognition Award, and Hope for Vision Visionary Award.
Richard Masland, PhD
Dr. Masland pioneered vision restoration with melanopsin at Harvard Medical School. He is Charles A. Pappas Professor of Neuroscience at Harvard Medical School and Neurophysiologist in Neurosurgery at Massachusetts General Hospital, Boston. He received his A.B. degree from Harvard College and his Ph.D. degree from McGill University. His postdoctoral work was done at Stanford and Harvard Medical Schools. Among his awards are the Hoopes Prize and Irving M. London Award, both for excellence in teaching, and the Brian Boycott Prize for research on the retina. Dr. Masland is a Senior Investigator of Research to Prevent Blindness. In 2009, Dr. Masland joined the Massachusetts Eye and Ear Infirmary. He serves as the David G. Cogan Professorship of Ophthalmology, director of the Howe Laboratory, and associate chief for ophthalmology research.
Edward “Ted” McGuire, PhD
Dr. McGuire has over 35 years of experience in pharmaceutical research and development, playing instrumental roles in the submission of numerous INDs, NDAs, and MAAs, including those for Lopid®, Accupril®, Neurontin®, Lipitor®, and Rezulin®. Dr. McGuire’s most recent positions include, Senior Director, Toxicological Sciences and Development at Parke-Davis, and Senior Scientific Advisor, Drug Safety Evaluation at Pfizer. While in these roles, Dr. McGuire’s held primary responsibilities for developing and implementing toxicology strategies that were aligned to meet regulatory requirements and ensuring expedient development of investigative drugs. During Dr. McGuire’s tenure within pharma companies, he has supervised discovery and development teams – including gene therapy programs – coordinated and developed global toxicology plans, designed, conducted, and interpreted preclinical safety studies and study results, and led the resolution of issues impacting drug development.
Select accomplishments for Dr. McGuire include: Chairmanship of the Task Force that submitted the Lipitor® IND, presentation of the Rezulin® toxicology profile to the Endocrinology and Metabolic Drugs Advisory Committee, and extensive interactions with domestic and international regulatory agencies. Dr. McGuire serves as a consultant for numerous pharmaceutical companies and, until recently, was an expert witness for Pfizer in Rezulin® product litigation. Additionally, Dr. McGuire served as President and Director of Regulatory Affairs for Cognitive Pharmaceuticals, Ltd.
Dr. McGuire received BSc and MSc degrees from the University of Windsor, Canada, and a PhD from The University of Michigan. He received a Distinguished Dissertation Award for his PhD thesis addressing hepatic effects of marketed lipid-regulating agents. He has published extensively and presented at numerous scientific meetings.
Hiroshi Tomita, PhD
Dr. Tomita is a Professor in the Department of Chemistry and Bioengineering at Iwate University. Dr. Tomita is an early pioneer in the use of optogenetics for vision restoration. His work has focused on both the safety and efficacy of optogenetic reagents in the retina, as well as engineered reagents for improved performance. He has published numerous papers on the subject from 2007 to present and holds one pending patent. Dr. Tomita is frequently invited to present his data at international ophthalmology conferences such as International Society of Eye Researchers (ISER), and Association for Research in Vision and Ophthalmology (ARVO).
(return to top of page)